EYPT
Price
$4.61
Change
-$0.00 (-0.00%)
Updated
Apr 7, 04:29 PM (EDT)
Capitalization
316.15M
23 days until earnings call
IBRX
Price
$2.67
Change
-$0.16 (-5.65%)
Updated
Apr 7, 04:43 PM (EDT)
Capitalization
2.42B
31 days until earnings call
Ad is loading...

EYPT vs IBRX

Header iconEYPT vs IBRX Comparison
Open Charts EYPT vs IBRXBanner chart's image
EyePoint Pharmaceuticals
Price$4.61
Change-$0.00 (-0.00%)
Volume$1.42K
Capitalization316.15M
ImmunityBio
Price$2.67
Change-$0.16 (-5.65%)
Volume$7.37K
Capitalization2.42B
EYPT vs IBRX Comparison Chart
Loading...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IBRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
EYPT vs. IBRX commentary
Apr 07, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is EYPT is a Hold and IBRX is a Hold.

Ad is loading...
COMPARISON
Comparison
Apr 07, 2025
Stock price -- (EYPT: $4.61 vs. IBRX: $2.83)
Brand notoriety: EYPT and IBRX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: EYPT: 183% vs. IBRX: 131%
Market capitalization -- EYPT: $316.15M vs. IBRX: $2.42B
EYPT [@Biotechnology] is valued at $316.15M. IBRX’s [@Biotechnology] market capitalization is $2.42B. The market cap for tickers in the [@Biotechnology] industry ranges from $283.79B to $0. The average market capitalization across the [@Biotechnology] industry is $2.18B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

EYPT’s FA Score shows that 1 FA rating(s) are green whileIBRX’s FA Score has 1 green FA rating(s).

  • EYPT’s FA Score: 1 green, 4 red.
  • IBRX’s FA Score: 1 green, 4 red.
According to our system of comparison, both EYPT and IBRX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

EYPT’s TA Score shows that 4 TA indicator(s) are bullish while IBRX’s TA Score has 4 bullish TA indicator(s).

  • EYPT’s TA Score: 4 bullish, 5 bearish.
  • IBRX’s TA Score: 4 bullish, 5 bearish.
According to our system of comparison, both EYPT and IBRX are a bad buy in the short-term.

Price Growth

EYPT (@Biotechnology) experienced а -20.93% price change this week, while IBRX (@Biotechnology) price change was -9.87% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -9.96%. For the same industry, the average monthly price growth was -18.52%, and the average quarterly price growth was -18.88%.

Reported Earning Dates

EYPT is expected to report earnings on Apr 30, 2025.

IBRX is expected to report earnings on May 08, 2025.

Industries' Descriptions

@Biotechnology (-9.96% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
IBRX($2.42B) has a higher market cap than EYPT($316M). IBRX YTD gains are higher at: 10.547 vs. EYPT (-38.121). EYPT has higher annual earnings (EBITDA): -129.23M vs. IBRX (-264.43M). EYPT has more cash in the bank: 371M vs. IBRX (150M). EYPT has less debt than IBRX: EYPT (21.9M) vs IBRX (504M). EYPT has higher revenues than IBRX: EYPT (43.3M) vs IBRX (14.7M).
EYPTIBRXEYPT / IBRX
Capitalization316M2.42B13%
EBITDA-129.23M-264.43M49%
Gain YTD-38.12110.547-361%
P/E RatioN/AN/A-
Revenue43.3M14.7M295%
Total Cash371M150M247%
Total Debt21.9M504M4%
FUNDAMENTALS RATINGS
EYPT vs IBRX: Fundamental Ratings
EYPT
IBRX
OUTLOOK RATING
1..100
6365
VALUATION
overvalued / fair valued / undervalued
1..100
62
Fair valued
3
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
97100
PRICE GROWTH RATING
1..100
8961
P/E GROWTH RATING
1..100
14100
SEASONALITY SCORE
1..100
n/a85

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

IBRX's Valuation (3) in the Biotechnology industry is somewhat better than the same rating for EYPT (62) in the Pharmaceuticals Major industry. This means that IBRX’s stock grew somewhat faster than EYPT’s over the last 12 months.

IBRX's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as EYPT (100) in the Pharmaceuticals Major industry. This means that IBRX’s stock grew similarly to EYPT’s over the last 12 months.

EYPT's SMR Rating (97) in the Pharmaceuticals Major industry is in the same range as IBRX (100) in the Biotechnology industry. This means that EYPT’s stock grew similarly to IBRX’s over the last 12 months.

IBRX's Price Growth Rating (61) in the Biotechnology industry is in the same range as EYPT (89) in the Pharmaceuticals Major industry. This means that IBRX’s stock grew similarly to EYPT’s over the last 12 months.

EYPT's P/E Growth Rating (14) in the Pharmaceuticals Major industry is significantly better than the same rating for IBRX (100) in the Biotechnology industry. This means that EYPT’s stock grew significantly faster than IBRX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
EYPTIBRX
RSI
ODDS (%)
Bullish Trend 7 days ago
90%
N/A
Stochastic
ODDS (%)
Bullish Trend 7 days ago
76%
Bullish Trend 7 days ago
82%
Momentum
ODDS (%)
Bearish Trend 7 days ago
90%
Bullish Trend 7 days ago
77%
MACD
ODDS (%)
Bearish Trend 7 days ago
90%
Bullish Trend 7 days ago
81%
TrendWeek
ODDS (%)
Bearish Trend 7 days ago
89%
Bullish Trend 7 days ago
85%
TrendMonth
ODDS (%)
Bearish Trend 7 days ago
90%
Bearish Trend 7 days ago
90%
Advances
ODDS (%)
Bullish Trend 15 days ago
84%
Bullish Trend 26 days ago
85%
Declines
ODDS (%)
Bearish Trend 7 days ago
89%
Bearish Trend 7 days ago
89%
BollingerBands
ODDS (%)
Bullish Trend 7 days ago
89%
Bearish Trend 7 days ago
88%
Aroon
ODDS (%)
Bearish Trend 7 days ago
87%
Bearish Trend 7 days ago
90%
View a ticker or compare two or three
Ad is loading...
EYPT
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
IBRX
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME23.492.39
+11.33%
GameStop Corp
SPY505.28-31.42
-5.85%
SPDR® S&P 500® ETF Trust
BTC.X78214.484000-5290.312500
-6.34%
Bitcoin cryptocurrency
AAPL188.38-14.81
-7.29%
Apple
TSLA239.43-27.85
-10.42%
Tesla

EYPT and

Correlation & Price change

A.I.dvisor indicates that over the last year, EYPT has been loosely correlated with LYRA. These tickers have moved in lockstep 58% of the time. This A.I.-generated data suggests there is some statistical probability that if EYPT jumps, then LYRA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To EYPT
1D Price
Change %
EYPT100%
-7.62%
LYRA - EYPT
58%
Loosely correlated
+8.55%
ATHE - EYPT
54%
Loosely correlated
-1.12%
OCUL - EYPT
54%
Loosely correlated
-9.21%
GLYC - EYPT
46%
Loosely correlated
-2.76%
BEAM - EYPT
43%
Loosely correlated
-7.23%
More

IBRX and

Correlation & Price change

A.I.dvisor indicates that over the last year, IBRX has been loosely correlated with CLRB. These tickers have moved in lockstep 38% of the time. This A.I.-generated data suggests there is some statistical probability that if IBRX jumps, then CLRB could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To IBRX
1D Price
Change %
IBRX100%
-4.71%
CLRB - IBRX
38%
Loosely correlated
-9.82%
ADCT - IBRX
35%
Loosely correlated
-4.07%
ANAB - IBRX
33%
Loosely correlated
-4.04%
EYPT - IBRX
33%
Loosely correlated
-7.62%
CGON - IBRX
33%
Poorly correlated
-8.22%
More